Related Experiment Videos
Combined immunosuppressive therapy in aplastic anaemia
1University of Ankara, School of Medicine, Department of Hematology, Ibn-i Sina Hospital, Ankara, Turkey.
The Indian Journal of Medical Research
|September 1, 1995
Summary
Combined immunosuppressive therapy, including Cyclosporin A, Antilymphocyte globulin, and Methylprednisolone, showed promising results for aplastic anaemia (AA) patients. This treatment offers a viable option for those ineligible for bone marrow transplantation.
Area of Science:
- Hematology
- Immunology
- Clinical Medicine
Background:
- Aplastic anaemia (AA) is a rare but serious bone marrow failure disorder.
- Treatment options for AA include bone marrow transplantation and immunosuppressive therapy.
- Identifying effective treatments for patients ineligible for transplantation is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of combined immunosuppressive treatment for aplastic anaemia.
- To assess remission rates in patients with severe and less severe AA.
Main Methods:
- Fifteen patients with AA received combined immunosuppressive treatment.
- Treatment involved intravenous Cyclosporin A (CsA), Antilymphocyte globulin serum (ALG), and oral Methylprednisolone (MP).
- Dosages and treatment durations were standardized, with serum levels and toxicities monitored.
Main Results:
- Complete remission (CR) was achieved in 7 patients (5 severe, 2 less severe).
- Partial remission (PR) was observed in 3 patients (1 severe, 2 less severe).
- One patient died due to infection; other toxicities were reversible.
Conclusions:
- Combined immunosuppressive therapy demonstrates significant efficacy in treating aplastic anaemia.
- This treatment regimen is a potential alternative for AA patients not eligible for bone marrow transplantation.
- Further research may optimize this therapeutic approach for better patient outcomes.